Is IONQ The Next NVIDIA?
Quantum computing startup IonQ (NYSE:IONQ) has seen its stock skyrocket…
Sell
44
SKIN Quote, Financials, Valuation and Earnings
Last price:
$1.60
Seasonality move
:
-1.93%
Day range:
$1.56 - $1.70
52-week range:
$0.78 - $2.26
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.67x
P/B ratio:
4.46x
Volume:
1.2M
Avg. volume:
937.1K
1-year change:
-25.23%
Market cap:
$205.4M
Revenue:
$334.3M
EPS (TTM):
-$0.41
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
SKIN
The Beauty Health
|
$63.1M | -$0.07 | -18.24% | -80% | $1.76 |
|
EWCZ
European Wax Center
|
$49.7M | $0.05 | -4.6% | 75.92% | $6.71 |
|
GROV
Grove Collaborative Holdings
|
$47M | -$0.03 | -14.72% | -67.86% | $2.10 |
|
HIMS
Hims & Hers Health
|
$538.9M | $0.23 | 73.98% | 273.73% | $47.56 |
|
KVUE
Kenvue
|
$3.7B | $0.23 | -1.27% | 835.9% | $24.75 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
SKIN
The Beauty Health
|
$1.63 | $1.76 | $205.4M | -- | $0.00 | 0% | 0.67x |
|
EWCZ
European Wax Center
|
$5.09 | $6.71 | $220.6M | 24.95x | $0.00 | 0% | 1.07x |
|
GROV
Grove Collaborative Holdings
|
$1.38 | $2.10 | $55.6M | -- | $0.00 | 0% | 0.27x |
|
HIMS
Hims & Hers Health
|
$56.56 | $47.56 | $12.7B | 81.97x | $0.00 | 0% | 7.64x |
|
KVUE
Kenvue
|
$23.87 | $24.75 | $45.8B | 43.40x | $0.21 | 3.44% | 3.00x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
SKIN
The Beauty Health
|
92.31% | 2.498 | 329.49% | 6.31x |
|
EWCZ
European Wax Center
|
84.28% | 3.372 | 189.52% | 1.88x |
|
GROV
Grove Collaborative Holdings
|
36.37% | 3.246 | 9.48% | 0.37x |
|
HIMS
Hims & Hers Health
|
-- | 7.831 | -- | 1.18x |
|
KVUE
Kenvue
|
46.19% | 0.455 | 18.75% | 0.58x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
SKIN
The Beauty Health
|
$48.6M | -$12M | -6.09% | -66.39% | -9.64% | $1.9M |
|
EWCZ
European Wax Center
|
$38.2M | $10.6M | 1.97% | 9.03% | 20.58% | $12M |
|
GROV
Grove Collaborative Holdings
|
$23.1M | -$3.5M | -49.78% | -164.34% | -7.33% | -$7.4M |
|
HIMS
Hims & Hers Health
|
$430.7M | $57.9M | 37.84% | 37.84% | 9.88% | $50.1M |
|
KVUE
Kenvue
|
$2.2B | $618M | 5.62% | 10.32% | 15.1% | $249M |
The Beauty Health vs. Competitors
-
Which has Higher Returns SKIN or EWCZ?
European Wax Center has a net margin of -14.51% compared to The Beauty Health's net margin of 3.37%. The Beauty Health's return on equity of -66.39% beat European Wax Center's return on equity of 9.03%.
Company Gross Margin Earnings Per Share Invested Capital SKINThe Beauty Health69.82% -$0.08 $599M EWCZEuropean Wax Center74.19% $0.04 $476.1M -
What do Analysts Say About SKIN or EWCZ?
The Beauty Health has a consensus price target of $1.76, signalling upside risk potential of 7.98%. On the other hand European Wax Center has an analysts' consensus of $6.71 which suggests that it could grow by 31.91%. Given that European Wax Center has higher upside potential than The Beauty Health, analysts believe European Wax Center is more attractive than The Beauty Health.
Company Buy Ratings Hold Ratings Sell Ratings SKINThe Beauty Health0 7 0 EWCZEuropean Wax Center3 4 1 -
Is SKIN or EWCZ More Risky?
The Beauty Health has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison European Wax Center has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock SKIN or EWCZ?
The Beauty Health has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. European Wax Center offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. The Beauty Health pays -- of its earnings as a dividend. European Wax Center pays out 7.54% of its earnings as a dividend. European Wax Center's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios SKIN or EWCZ?
The Beauty Health quarterly revenues are $69.6M, which are larger than European Wax Center quarterly revenues of $51.4M. The Beauty Health's net income of -$10.1M is lower than European Wax Center's net income of $1.7M. Notably, The Beauty Health's price-to-earnings ratio is -- while European Wax Center's PE ratio is 24.95x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for The Beauty Health is 0.67x versus 1.07x for European Wax Center. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SKINThe Beauty Health0.67x -- $69.6M -$10.1M EWCZEuropean Wax Center1.07x 24.95x $51.4M $1.7M
-
Which has Higher Returns SKIN or GROV?
Grove Collaborative Holdings has a net margin of -14.51% compared to The Beauty Health's net margin of -8.15%. The Beauty Health's return on equity of -66.39% beat Grove Collaborative Holdings's return on equity of -164.34%.
Company Gross Margin Earnings Per Share Invested Capital SKINThe Beauty Health69.82% -$0.08 $599M GROVGrove Collaborative Holdings52.96% -$0.10 $20.6M -
What do Analysts Say About SKIN or GROV?
The Beauty Health has a consensus price target of $1.76, signalling upside risk potential of 7.98%. On the other hand Grove Collaborative Holdings has an analysts' consensus of $2.10 which suggests that it could grow by 52.17%. Given that Grove Collaborative Holdings has higher upside potential than The Beauty Health, analysts believe Grove Collaborative Holdings is more attractive than The Beauty Health.
Company Buy Ratings Hold Ratings Sell Ratings SKINThe Beauty Health0 7 0 GROVGrove Collaborative Holdings1 1 0 -
Is SKIN or GROV More Risky?
The Beauty Health has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Grove Collaborative Holdings has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock SKIN or GROV?
The Beauty Health has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Grove Collaborative Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. The Beauty Health pays -- of its earnings as a dividend. Grove Collaborative Holdings pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SKIN or GROV?
The Beauty Health quarterly revenues are $69.6M, which are larger than Grove Collaborative Holdings quarterly revenues of $43.5M. The Beauty Health's net income of -$10.1M is lower than Grove Collaborative Holdings's net income of -$3.5M. Notably, The Beauty Health's price-to-earnings ratio is -- while Grove Collaborative Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for The Beauty Health is 0.67x versus 0.27x for Grove Collaborative Holdings. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SKINThe Beauty Health0.67x -- $69.6M -$10.1M GROVGrove Collaborative Holdings0.27x -- $43.5M -$3.5M
-
Which has Higher Returns SKIN or HIMS?
Hims & Hers Health has a net margin of -14.51% compared to The Beauty Health's net margin of 8.44%. The Beauty Health's return on equity of -66.39% beat Hims & Hers Health's return on equity of 37.84%.
Company Gross Margin Earnings Per Share Invested Capital SKINThe Beauty Health69.82% -$0.08 $599M HIMSHims & Hers Health73.5% $0.20 $549.3M -
What do Analysts Say About SKIN or HIMS?
The Beauty Health has a consensus price target of $1.76, signalling upside risk potential of 7.98%. On the other hand Hims & Hers Health has an analysts' consensus of $47.56 which suggests that it could fall by -15.9%. Given that The Beauty Health has higher upside potential than Hims & Hers Health, analysts believe The Beauty Health is more attractive than Hims & Hers Health.
Company Buy Ratings Hold Ratings Sell Ratings SKINThe Beauty Health0 7 0 HIMSHims & Hers Health4 6 1 -
Is SKIN or HIMS More Risky?
The Beauty Health has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Hims & Hers Health has a beta of 2.094, suggesting its more volatile than the S&P 500 by 109.43%.
-
Which is a Better Dividend Stock SKIN or HIMS?
The Beauty Health has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Hims & Hers Health offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. The Beauty Health pays -- of its earnings as a dividend. Hims & Hers Health pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SKIN or HIMS?
The Beauty Health quarterly revenues are $69.6M, which are smaller than Hims & Hers Health quarterly revenues of $586M. The Beauty Health's net income of -$10.1M is lower than Hims & Hers Health's net income of $49.5M. Notably, The Beauty Health's price-to-earnings ratio is -- while Hims & Hers Health's PE ratio is 81.97x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for The Beauty Health is 0.67x versus 7.64x for Hims & Hers Health. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SKINThe Beauty Health0.67x -- $69.6M -$10.1M HIMSHims & Hers Health7.64x 81.97x $586M $49.5M
-
Which has Higher Returns SKIN or KVUE?
Kenvue has a net margin of -14.51% compared to The Beauty Health's net margin of 8.61%. The Beauty Health's return on equity of -66.39% beat Kenvue's return on equity of 10.32%.
Company Gross Margin Earnings Per Share Invested Capital SKINThe Beauty Health69.82% -$0.08 $599M KVUEKenvue57.95% $0.17 $18.7B -
What do Analysts Say About SKIN or KVUE?
The Beauty Health has a consensus price target of $1.76, signalling upside risk potential of 7.98%. On the other hand Kenvue has an analysts' consensus of $24.75 which suggests that it could grow by 3.7%. Given that The Beauty Health has higher upside potential than Kenvue, analysts believe The Beauty Health is more attractive than Kenvue.
Company Buy Ratings Hold Ratings Sell Ratings SKINThe Beauty Health0 7 0 KVUEKenvue3 14 0 -
Is SKIN or KVUE More Risky?
The Beauty Health has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Kenvue has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock SKIN or KVUE?
The Beauty Health has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Kenvue offers a yield of 3.44% to investors and pays a quarterly dividend of $0.21 per share. The Beauty Health pays -- of its earnings as a dividend. Kenvue pays out 150.68% of its earnings as a dividend.
-
Which has Better Financial Ratios SKIN or KVUE?
The Beauty Health quarterly revenues are $69.6M, which are smaller than Kenvue quarterly revenues of $3.7B. The Beauty Health's net income of -$10.1M is lower than Kenvue's net income of $322M. Notably, The Beauty Health's price-to-earnings ratio is -- while Kenvue's PE ratio is 43.40x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for The Beauty Health is 0.67x versus 3.00x for Kenvue. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SKINThe Beauty Health0.67x -- $69.6M -$10.1M KVUEKenvue3.00x 43.40x $3.7B $322M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Best AI Index Fund to Buy
Over the last two years, companies with a focus on…
Where Will Salesforce Stock Be in 5 Years?
Salesforce (NYSE: CRM) just turned in a quarter that, on…
Stock Ideas
Buy
67
Is MSFT Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 39x
Buy
65
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 46x
Buy
52
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Alerts
Sell
31
REGN alert for Jun 2
Regeneron Pharmaceuticals [REGN] is up 0.05% over the past day.
Buy
55
RGC alert for Jun 2
Regencell Bioscience Holdings [RGC] is down 19.04% over the past day.
Sell
42
AMBA alert for Jun 2
Ambarella [AMBA] is up 0.93% over the past day.
